

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Lorcaserin hydrochloride for the treatment of obesity and overweight

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Arena Pharmaceuticals (lorcaserin hydrochloride) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Heart • Afiya Trust • Beat • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Diabetes UK • Equalities National Council • Healthier Weight Centres • Heart Care Partnership UK • HEART UK • Insulin Dependent Diabetes Trust • Muslim Council of Great Britain • Muslim Health Network • National Obesity Forum • South Asian Health Foundation • Specialised Healthcare Alliance • The Overweight and Obesity Organisation • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • Association of Diabetes Specialist Nurses 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Commissioning Support Appraisals Services • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Medicines and Healthcare products Regulatory Agency (MHRA) • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Clinical Obesity Group • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Abbott Laboratories (sibutramine) • GlaxoSmithKline Consumer Healthcare (orlistat) • Roche Products (orlistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research (BCS affiliated) • Cardiovascular Diseases Specialist Library • Cochrane Heart Group • Cochrane Peripheral Vascular Disease Group

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Nursing in Cardiac Care • British Association for Services to the Elderly • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatric Society • British Heart Foundation • British Hypertension Society • British Nutrition Foundation • Diabetes Monitoring Forum • Dieticians in Obesity Management • Faculty of Public Health Medicine • National Centre for Eating Disorders • National Heart Forum UK • Primary Care Cardiovascular Society • Primary Care Diabetes UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society for Endocrinology • Society for Cardiological Science & Technology • Society for Vascular Technology • Society for Vascular Nurses • The Nutrition Society • The Obesity Management Association • United Kingdom Clinical Pharmacy Association • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Hastings and Rother • NHS North Staffordshire • Welsh Assembly Government 	<ul style="list-style-type: none"> • Corda • Diabetes Foundation • Diabetes Research & Wellness Foundation • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • Wellcome Trust – Cardiovascular Research Initiative <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight

Issue date: January 2010

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.